Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
Jonas Busch(Charité - Universitätsmedizin Berlin), Viktor Grünwald(Deutsche Schmerzgesellschaft), Stefan Hinz(Charité - Universitätsmedizin Berlin), Lisa Weinkauf(Charité - Universitätsmedizin Berlin), Christoph Seidel(Medizinische Hochschule Hannover), Ingmar Wolff(Universitätsmedizin Greifswald), Ahmed Magheli(Johns Hopkins University), Kurt Miller(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin)
Cited by 54
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
The Effect of Exercise Training Programs on Bone Mass: A Meta-analysis of Published Controlled Trials in Pre- and Postmenopausal Women
|Osteoporosis International|1999|594